PMID- 3501509
OWN - NLM
STAT- MEDLINE
DCOM- 19880315
LR  - 20061115
IS  - 0277-6766 (Print)
IS  - 0277-6766 (Linking)
VI  - 6
IP  - 4
DP  - 1987 Fall
TI  - Adjuvant activity of the 163-171 peptide of human IL-1 beta administered through 
      different routes.
PG  - 335-9
AB  - The synthetic peptide VQGEESNDK, corresponding to the fragment 163-171 of human 
      IL-1 beta, could potently enhance the primary and secondary response of mice 
      immunized with SRBC, measured as the number of specific antibody-secreting cells 
      in the spleen. This adjuvant activity was dose-dependent, being maximal when the 
      nonapeptide was administered intraperitoneally (i.p.) or subcutaneously (s.c.) at 
      100 mg/kg or orally (p.os) at 33 mg/kg, reaching levels comparable to those 
      attained by 20 ng/kg of hu rIL-1 beta given i.p. or s.c. A dose-dependent 
      enhancement of the primary response to SRBC was also observed when IL-1 beta or 
      its peptide fragment were injected intravenously (i.v.) together with the 
      antigen, with a maximum activity at 10 micrograms/kg for the 163-171 peptide and 
      100 pg/kg for hu rIL-1 beta. Thus, the in vivo immunostimulatory activity of hu 
      IL-1 beta depended on the administration route as follows: i.v. much greater than 
      s.c. = i.p. much greater than p.os. Conversely, the adjuvant effect of the 
      163-171 peptide was: i.v. much greater than p.os greater than s.c. = i.p.
FAU - Nencioni, L
AU  - Nencioni L
AD  - Sclavo Research Center, Siena, Italy.
FAU - Villa, L
AU  - Villa L
FAU - Tagliabue, A
AU  - Tagliabue A
FAU - Boraschi, D
AU  - Boraschi D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Lymphokine Res
JT  - Lymphokine research
JID - 8308208
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Interleukin-1)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Peptide Fragments)
RN  - 0 (Recombinant Proteins)
RN  - 106021-96-9 (interleukin-1beta (163-171))
SB  - IM
MH  - Adjuvants, Immunologic/*metabolism
MH  - Administration, Oral
MH  - Animals
MH  - Antibody Formation/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Injections, Intraperitoneal
MH  - Injections, Subcutaneous
MH  - Interleukin-1/administration & dosage/biosynthesis/*immunology
MH  - Interleukin-1beta
MH  - Male
MH  - Mice
MH  - Mice, Inbred C3H
MH  - Peptide Fragments/administration & dosage/biosynthesis/*immunology
MH  - Recombinant Proteins/administration & dosage/immunology
MH  - Spleen/drug effects/immunology
EDAT- 1987/01/01 00:00
MHDA- 1987/01/01 00:01
CRDT- 1987/01/01 00:00
PHST- 1987/01/01 00:00 [pubmed]
PHST- 1987/01/01 00:01 [medline]
PHST- 1987/01/01 00:00 [entrez]
PST - ppublish
SO  - Lymphokine Res. 1987 Fall;6(4):335-9.